Privately held and clinical-stage, Molecular Targeting Technologies, Inc. is known for advancing radiopharmaceutical research aimed at rare cancers. Its EvaThera platform, licensed worldwide from the National Institutes of Health, supports targeted diagnosis and treatment for patients whose tumors express specific molecular markers.